Vesilute
Bladder & urinary tract Research only Preliminary Synthetic short peptide (Cytogen)
Also called ED dipeptide
A two-amino-acid Khavinson peptide associated with bladder and urinary tract tissue. Reports describe better bladder function in older adults and effects on prostate tissue. It is one of the least studied peptides in this family.
Evidence at a glance
- Evidence
- Preliminary — Very little published work
- Status
- Research compound only
- Dosing
- No human study has set a dose
One of the least studied peptides in this family.
What studies report
- Reported improvement in bladder function in older adults
- Effects on prostate tissue in animal reports
How it works
A Khavinson short peptide: at two to four amino acids it is small enough to pass through cell and nuclear membranes intact. The proposed mechanism is that it binds specific sites on nuclear DNA and changes which genes are switched on in its target tissue, rather than acting on a surface receptor the way most peptides do.
Where it acts
BladderThe library groups this compound under Bladder & urinary tract. The diagram shows that target, not every tissue it reaches.
Illustrated
AI-generated subject illustration; not a depiction of the compound or evidence of its effects.
Why people take it
Reasons people seek it out — not a list of proven effects.
Status: Limited data, mostly from one research group.
- Route
- Subcutaneous injection, or oral capsule depending on the preparation
- Sequence
- Glu-Asp
- Formula
- C9H14N2O7
- Molecular weight
- 262.22 g/mol
- CAS
- 3918-84-1
- Available as
- 20 mg
Search PubMed for Vesilute → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.
Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.